Amplia Expands US Footprint for Pancreatic Cancer Trial with Two New Sites
Event summary
- Amplia Therapeutics has opened two US clinical trial sites for its AMPLICITY pancreatic cancer study, joining two existing Australian sites.
- The new sites are University of California, Irvine and The Cleveland Clinic, with three additional US sites expected to open soon.
- The AMPLICITY trial investigates narmafotinib (AMP945) combined with modified FOLFIRINOX chemotherapy for advanced pancreatic cancer patients.
- The trial is designed as a Phase 1b/2a study following FDA's Project Optimus guidance for oncology therapies.
The big picture
Amplia's expansion into US clinical sites represents a strategic pivot to access larger patient populations and strengthen its presence in the world's largest pharmaceutical market. The move comes as pancreatic cancer remains one of the most challenging oncology indications, with limited treatment options and high unmet medical need. The company's focus on FAK inhibition positions it within an emerging class of targeted therapies aiming to improve outcomes in fibrotic tumors.
What we're watching
- Trial Momentum
- Whether the additional US sites will accelerate patient enrollment and meet projected timelines for the AMPLICITY study.
- Regulatory Pathway
- How the FDA's Project Optimus framework will influence the design and outcomes of this adaptive trial structure.
- Competitive Positioning
- The pace at which Amplia can differentiate narmafotinib in the crowded pancreatic cancer treatment landscape.
Our editorial coverage:
Related topics